Zhitong Finance App News, Jingfang Pharmaceutical-B (02595.HK) announced that since the third quarter of this year, several innovative combination therapies for oral administration of the RAS inhibitor GFH276 have obtained clinical trial licenses issued by the domestic CDE or completed the Australian TGA clinical trial registration. Relevant studies cover first-line and post-line treatment of multiple high-indication RAS mutations, and some trials have enrolled patients at multiple dose levels.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.